Cancer

Immunotherapy: Bad B cells

Nature Rev. Cancer - 25 January 2018 - 12:00am

Immunotherapy: Bad B cells

Immunotherapy: Bad B cells, Published online: 25 January 2018; doi:10.1038/nrc.2018.7

Immunotherapy: Bad B cells
Categories: Cancer

Gastric cancer: Risk analysis

Nature Rev. Cancer - 25 January 2018 - 12:00am

Gastric cancer: Risk analysis

Gastric cancer: Risk analysis, Published online: 25 January 2018; doi:10.1038/nrc.2018.9

Gastric cancer: Risk analysis
Categories: Cancer

EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma

Cell Cancer - 23 January 2018 - 12:00am
Iniguez et al. find that inhibition of CDK12 is synthetic lethal with EWS/FLI expression. CDK12/13 inhibitors impair DNA damage repair in cells expressing EWS/FLI, and the combination of CDK12/13 and PARP inhibitors synergistically reduces tumor growth and extends survival in Ewing sarcoma mouse models.
Categories: Cancer

A matter of life and death: stem cell survival in tissue regeneration and tumour formation

Nature Rev. Cancer - 19 January 2018 - 12:00am

A matter of life and death: stem cell survival in tissue regeneration and tumour formation

A matter of life and death: stem cell survival in tissue regeneration and tumour formation, Published online: 19 January 2018; doi:10.1038/nrc.2017.122

Stem cells are long-lived and possess unique mechanisms related to quiescence, DNA damage response and apoptosis that protect them throughout their lifespan and during tissue repair. These mechanisms may also have a role in cancer stem cells and tumorigenesis.
Categories: Cancer

Targeting B cell receptor signalling in cancer: preclinical and clinical advances

Nature Rev. Cancer - 19 January 2018 - 12:00am

Targeting B cell receptor signalling in cancer: preclinical and clinical advances

Targeting B cell receptor signalling in cancer: preclinical and clinical advances, Published online: 19 January 2018; doi:10.1038/nrc.2017.121

In this Review, Burger and Wiestner describe the latest insights into B cell receptor (BCR) signalling with respect to its contribution to B cell malignancies and discuss how inhibitors that target kinases downstream of the BCR are changing treatment outcomes for patients with B cell neoplasms.
Categories: Cancer

EMT in cancer

Nature Rev. Cancer - 12 January 2018 - 12:00am

EMT in cancer

EMT in cancer, Published online: 12 January 2018; doi:10.1038/nrc.2017.118

In this Viewpoint article, we asked four scientists working in the field of epithelial to mesenchymal transition (EMT) to provide their opinions on the role of this complicated phenomenon in cancer biology as well as the challenges of this fast-moving field and the directions it should take in the future.
Categories: Cancer

Impact of oncogenic pathways on evasion of antitumour immune responses

Nature Rev. Cancer - 12 January 2018 - 12:00am

Impact of oncogenic pathways on evasion of antitumour immune responses

Impact of oncogenic pathways on evasion of antitumour immune responses, Published online: 12 January 2018; doi:10.1038/nrc.2017.117

This Review describes tumour cell-intrinsic oncogenic pathways implicated in tumour immune evasion and highlights the potential for targeting these pathways to overcome resistance to immunotherapy in various cancer types.
Categories: Cancer

Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma

Cell Cancer - 8 January 2018 - 12:00am
(Cancer Cell 32, 204–220; August 14, 2017)
Categories: Cancer

Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer

Cell Cancer - 8 January 2018 - 12:00am
(Cancer Cell 32, 574–589; November 13, 2017)
Categories: Cancer

Characterizing the Killer Colorectal Carcinomas

Cell Cancer - 8 January 2018 - 12:00am
In this issue of Cancer Cell, Yaeger et al. report mutations, copy number variations, and selected rearrangements from a large series of metastatic colorectal carcinomas and primaries that produced metastases. The results provide important insights into differences in anatomical site of origin, age at onset, etiologic factors, and therapeutic responses.
Categories: Cancer

TFIID and MYB Share a Therapeutic Handshake in AML

Cell Cancer - 8 January 2018 - 12:00am
Selectively disrupting oncogenic transcription factors in cancer remains an elusive ambition of targeted therapeutics. In this issue of Cancer Cell, Xu et al. provide an elegant proof-of-concept study demonstrating that interaction between MYB and the general transcriptional coactivator TFIID can be specifically disrupted to mediate a therapeutic effect in AML.
Categories: Cancer

BET’ing on Dual JAK/BET Inhibition as a Therapeutic Strategy for Myeloproliferative Neoplasms

Cell Cancer - 8 January 2018 - 12:00am
In this issue of Cancer Cell, Kleppe et al. describe a combination strategy designed to inhibit BET bromodomain and JAK/STAT signaling as a method for effectively inhibiting NF-κB and cytokine production in myeloproliferative neoplasms (MPNs). The results provide a strong rationale for clinical evaluation of dual BET/JAK inhibition in MPNs.
Categories: Cancer

Molecular Predictors of Gastric Neoplastic Progression

Cell Cancer - 8 January 2018 - 12:00am
In this issue of Cancer Cell, Huang et al. describe comprehensive genetic and epigenetic profiling of gastric intestinal metaplasia lesions from a longitudinal cohort in which outcome data allowed for identification of potential markers of gastric neoplastic progression.
Categories: Cancer

What’s in a Name? Cell Fate Reprogramming in Sarcomagenesis

Cell Cancer - 8 January 2018 - 12:00am
Differentiation features in cancer cells are typically attributed to the cell of origin. In this issue of Cancer Cell, Drummond et al. demonstrate a transdifferentiation program apparent in rhabdomyosarcomas (cancers with skeletal muscle differentiation features) arising through cell fate reprogramming from a single oncogene activation in endothelial cell precursors.
Categories: Cancer

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer

Cell Cancer - 8 January 2018 - 12:00am
Yaeger et al. perform prospective sequencing of metastatic colorectal cancers (mCRCs). Right-sided primary microsatellite stable mCRCs are associated with increased oncogenic mutations whereas most left-sided tumors lack identifiable genetic mitogenic signaling alterations but highly express mitogenic ligands.
Categories: Cancer

Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-Asparaginase

Cell Cancer - 8 January 2018 - 12:00am
Gwinn et al. show that oncogenic KRAS regulates amino acid homeostasis and cellular response to nutrient stress via ATF4. They identify ASNS as a key target of the KRAS-ATF4 axis in KRAS-driven non-small-cell lung cancer, revealing a therapeutic vulnerability in asparagine biosynthesis.
Categories: Cancer

A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia

Cell Cancer - 8 January 2018 - 12:00am
Xu et al. show that TAF12 is a coactivator of MYB and protects MYB from degradation. TAF12, in a heterodimer with TAF4, interacts with the transactivation domain of MYB. Perturbation of this interaction by squelching TAF12 impairs MYB activity and leads to regression of acute myeloid leukemia in mouse models.
Categories: Cancer

Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors

Cell Cancer - 8 January 2018 - 12:00am
Using genetic fate mapping, Drummond et al. show that hedgehog pathway activation in endothelial progenitors results in aberrant expression of myogenic specification factors, myogenic transdifferentiation, and rhabdomyosarcoma (RMS). The finding may explain how RMS develops in sites devoid of skeletal muscle.
Categories: Cancer

TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer

Cell Cancer - 8 January 2018 - 12:00am
de Mingo Pulido et al. show that intratumoral CD103+ dendritic cells (DCs) highly express TIM-3. Anti-TIM-3 antibody promotes CXCL9 expression by these DCs, which enhances the function of CD8+ T cells, thereby improving paclitaxel's therapeutic activity in breast cancer models.
Categories: Cancer

Pages